05 Aug 2015 --- A recently published randomized, double-blind, placebo-controlled, crossover study by German investigators has tested the hypothesis that (-) epigallaocatechin-3-gallate (EGCG) treatment improves energy metabolism and substrate utilization in male and female Multiple Sclerosis patients during exercise.
